Radiofrequency treatment of hepatic neoplasms in patients with permanent pacemakers.
Clinicians who provide care for patients with implantable devices for rhythm management, ie, pacemakers and internal cardioverter defibrillators, must be aware of sources of interference that could affect device function. Intracardiac radiofrequency is a recognized source of potential interference. However, radiofrequency to extracardiac sites that are relatively close to the implanted device has not been investigated thoroughly. We present 2 patients with permanent pacemakers undergoing intrahepatic radiofrequency for the treatment of metastatic disease. No interference was documented in either patient. Additional in vitro and in vivo studies are needed to determine definite clinical guidelines for such patients.
Hayes
D L
DL
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA. dhayes@mayo.edu
Charboneau
J W
JW
Lewis
B D
BD
Asirvatham
S J
SJ
Dupuy
D E
DE
Lexvold
N Y
NY
D000368:Aged; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000556:secondary / Q000601:surgery; D017115:Catheter Ablation / Q000009:adverse effects / Q000379:methods*; D005500:Follow-Up Studies; D006327:Heart Block / Q000628:therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology / Q000601:surgery; D008113:Liver Neoplasms / Q000556:secondary* / Q000601:surgery*; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial; D018570:Risk Assessment